Evidence limits when counselling hereditary high‑risk women about hormonal contraception and colorectal cancer

Agreement: I AgreeBody:

Dear Editor,

Lange and colleagues deliver a landmark nationwide cohort investigating contemporary hormonal contraception and colorectal cancer (CRC) among premenopausal women¹. Their large-scale, registry-based analysis with extensive sensitivity analyses provides reassuring real-world evidence for routine reproductive health counselling. Nevertheless, several important boundaries should be emphasised to prevent over-interpretation of these findings in everyday clinical practice.

The primary null association is derived mainly from average-risk women. Although participants with prior cancer were excluded at baseline, the study lacks stratified analyses for women with known inherited CRC predispositions such as Lynch syndrome, familial adenomatous polyposis, or strong multigenerational family history of colorectal neoplasia. These high-risk subgroups carry substantially elevated baseline risk of early-onset CRC. It remains unknown whether exogenous sex-hormone exposure from modern contraceptives accelerates or suppresses neoplastic progression among mutation carriers. Clinicians therefore should not directly generalise the overall null result to these vulnerable patient populations. Contraceptive decision-making for mutation carriers still requires individualised multidisciplinary risk assessment.

Furthermore, the main adjusted incidence rate ratio was 0.94 with a 95% confidence interval spanning 0.83 to 1.06. This interval cannot exclude small-magnitude protective or harmful effects on CRC risk. As with all observational registry studies, residual confounding cannot be fully eliminated, even after careful adjustment. For average-risk premenopausal women, CRC risk should consequently not serve as a decisive factor when initiating or continuing hormonal contraception. Patient counselling ought to prioritise well-validated cancer-related benefits and risks: reduced risk of ovarian and endometrial cancer, alongside the well-documented modest excess risk of breast cancer associated with hormonal contraceptive use.

Crucially, these findings must not reduce clinical vigilance for CRC among young women. Early-onset colorectal cancer incidence keeps rising globally. Regardless of contraceptive status, persistent alarm gastrointestinal symptoms in women under 50 deserve timely diagnostic work-up. This study supports that modern hormonal contraception is unlikely to drive this rising trend, but cannot rule out minor effects in poorly characterised subgroups. Future registry or cohort research focusing specifically on women with hereditary CRC syndromes would help close this critical evidence gap for high-risk populations.

Reference

1. Lange IH, Hemmingsen CH, Meaidi A, etal. Contemporary hormonal contraception and colorectal cancer in premenopausal women: nationwide cohort study. BMJ 2026;394:e100065. doi: 10.1136/bmj-2026-100065.

Chengcheng Xia
xcc2025666nx@163.com
Department of Head and Neck Oncology, Yuebei People's Hospital, Shaoguan, Guangdong, China

No competing Interests: YesThe following competing Interests: Electronic Publication Date: Sunday, September 20, 2026 - 01:09AI use: No, I have not used AIHighwire Comment Subject:

Contemporary hormonal contraception and colorectal cancer in premenopausal women: nationwide cohort study

Workflow State: ReleasedFull Title:

Evidence limits when counselling hereditary high‑risk women about hormonal contraception and colorectal cancer

Highwire Comment Response to:

Contemporary hormonal contraception and colorectal cancer in premenopausal women: nationwide cohort study

Check this box if you would like your letter to appear anonymously:: Last Name: ChengchengFirst name and middle initial: XiaEmail:

xcc2025666nx@163.com

Address: 133 South Huimin Road, Wujiang District, Shaoguan City, Guangdong Province, P.R.ChinaOccupation: Department of Head and Neck OncologyAffiliation: Yuebei People's HospitalBMJ: Additional Article Info: Rapid response